Seelos therapeutics announces encouraging data from an in vivo study of sls-005 in an aggressive preclinical model of alzheimer's disease

- treatment with sls-005 demonstrated a 46% reduction in tau protein and an 18% reduction in nfl biomarker from baseline values within six months   - seelos has been selected to present these data at neuroscience 2023 to be held on november 11-15, 2023 in washington, d.c.  new york , sept.
SEEL Ratings Summary
SEEL Quant Ranking